Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience

Hiromichi Takahashi; Haruna Nishimaki; Yoko Nakanishi; Takashi Hamada; Masaru Nakagawa; Kazuhide Iizuka; Yoshihito Uchino; Noriyoshi Iriyama; Katsuhiro Miura; Tomohiro Nakayama; Shinobu Masuda; Yoshihiro Hatta; Hideki Nakamura

doi:10.1002/jha2.380

eJHaem (May 2022)

Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience

Hiromichi Takahashi,
Haruna Nishimaki,
Yoko Nakanishi,
Takashi Hamada,
Masaru Nakagawa,
Kazuhide Iizuka,
Yoshihito Uchino,
Noriyoshi Iriyama,
Katsuhiro Miura,
Tomohiro Nakayama,
Shinobu Masuda,
Yoshihiro Hatta,
Hideki Nakamura

Affiliations

Hiromichi Takahashi: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Haruna Nishimaki: Department of Pathology and Microbiology Division of Oncologic Pathology Nihon University School of Medicine Tokyo Japan
Yoko Nakanishi: Department of Pathology and Microbiology Division of Oncologic Pathology Nihon University School of Medicine Tokyo Japan
Takashi Hamada: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Masaru Nakagawa: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Kazuhide Iizuka: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Yoshihito Uchino: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Noriyoshi Iriyama: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Katsuhiro Miura: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Tomohiro Nakayama: Department of Pathology and Microbiology Division of Laboratory Medicine Nihon University School of Medicine Tokyo Japan
Shinobu Masuda: Department of Pathology and Microbiology Division of Oncologic Pathology Nihon University School of Medicine Tokyo Japan
Yoshihiro Hatta: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Hideki Nakamura: Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan

DOI: https://doi.org/10.1002/jha2.380
Journal volume & issue: Vol. 3, no. 2
pp. 467 – 470

Abstract

Read online

Abstract Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients with de novo IVLBCL treated at our hospital between 2004 and 2018 with either standard therapy plus CNS‐directed therapy or standard therapy alone. CNS‐directed therapy was associated with a significantly better 2‐year CNS‐free survival (100% vs. 63%, p = 0.0191), despite no significant effects on progression‐free or overall survival. Further studies should assess CNS‐focused treatment in patients with IVLBCL with or without primary CNS involvement.

Published in eJHaem

ISSN: 2688-6146 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: https://onlinelibrary.wiley.com/journal/26886146

About the journal

Abstract

Keywords